|Articles|December 16, 2013

BioPharm International

  • BioPharm International-12-16-2013
  • Volume 2013 eBook
  • Issue 1

Creating Better Medicines through Better Conjugation

Clinical-stage biopharmaceutical company Ambrx leverages its site-specific bioconjugation technology through partnerships.

 

Clinical-stage biopharmaceutical company Ambrx leverages its site-specific bioconjugation technology through partnerships to bring drugs with enhanced stability and bioactivity to market.

Read this article

from BioPharm International’s 2013 Innovation Updates and Strategies eBook.

 

 

 

 

 

 

 

Articles in this issue

about 12 years ago

Recovering Patent Life with Patent Term Extension

about 12 years ago

Strategic Outsourcing in Clinical Development

about 12 years ago

Leveraging Development Strengths Drives Therapies to Market

about 12 years ago

Driving Innovation in Biopharmaceuticals

about 12 years ago

Crowdfunding Biopharmaceutical Innovation

about 12 years ago

Restructuring for Biopharmaceutical Success

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Subscribe Now!

Related Content